SABSW Overview

Initiation of SAFEGUARD Trial: SAB Biotherapeutics has launched the registrational Phase 2b SAFEGUARD trial for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, with plans to dose the first patient by year-end.

Clinical Data Presentation: Recent presentations at EASD and ISPAD highlighted the favorable safety profile and multi-specific mechanism of action of SAB-142, reinforcing its potential as a disease-modifying treatment for T1D.

Financial Position: As of September 30, 2025, SAB Biotherapeutics reported a strong cash position of $161.5 million, enabling continued investment in the SAB-142 program and other research activities.

Upcoming Milestones: The company is on track to share additional data from the SAFEGUARD trial in the second half of 2027 and finalize Phase 1 study results by the end of this year.

SAB-142 Phase 2b Study Initiation: SAB Biotherapeutics has launched its Phase 2b SAFEGUARD study for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, and engaged with T1D thought leaders at the EASD Annual Meeting.

Validation of SAB-142's Efficacy: Presentations at EASD highlighted SAB-142's potential as a best-in-class immunotherapy for T1D, demonstrating a clinically validated mechanism of action and favorable pharmacokinetic profile, while also confirming the disease-modifying effects of rabbit ATG in a related study.

Funding Announcement: SAB BIO has secured $175 million in a private placement financing, with participation from strategic and new investors, to fund its Phase 2b SAFEGUARD study for delaying progression of autoimmune type 1 diabetes (T1D) in newly diagnosed patients.

Financial Outlook: The proceeds are expected to extend the company's cash runway into mid-2028, with potential additional gross proceeds of up to $284 million if milestone-based warrants are fully exercised.

Financial Performance and Developments: SAB BIO reported a net loss of $5.2 million for Q1 2025, with cash reserves decreasing to $12.9 million. The company is focusing on cost-saving initiatives and has achieved compliance for its manufacturing process in Europe.

Clinical Progress: The company announced positive Phase 1 data for its lead product, SAB-142, aimed at delaying type 1 diabetes progression, and completed patient dosing in the final cohort of the Phase 1 clinical study.

Phase 1 Enrollment Completion: SAB BIO has completed enrollment for its Phase 1 study of SAB-142, a treatment aimed at delaying type 1 diabetes (T1D), with no observed serum sickness and is on track for topline data by the end of the year.

Financial Overview: The company reported a net loss of $10.3 million for Q3 2024, with increased research and development expenses as it advances its T1D program, while maintaining sufficient cash to fund operations into 2026 if outstanding warrants are exercised.

Company Announcement: SAB BIO, a clinical-stage biopharmaceutical company, will have its Chairman and CEO Samuel J. Reich speaking at the 2024 Guggenheim Securities Healthcare Innovation Conference in Boston on November 11, 2024.

Company Focus: SAB BIO is developing human anti-thymocyte immunoglobulin (hIgG) aimed at delaying the onset or progression of type 1 diabetes, utilizing advanced genetic engineering to create high-potency immunoglobulins without needing human donors.